戻る Agenda
Artificial Intelligence: A Disruptive Journey for Pharmacovigilance
Session Chair(s)
Annette S. Williams, MBA, RPH
Vice President, Pharmacovigilance
IQVIA, United States
Pharmacovigilance is undergoing an unprecedented amount of change. As the global regulatory environment becomes more complex, PV departments are simultaneously faced with ever increasing volumes and varieties of safety data further stretching already limited resources. How can PV units become proactive and patient centric if they are overburdened by highly labor intensive processes? The rapidly evolving world of artificial intelligence and machine learning holds significant promise. This session will explore the real life journey of several organizations engaged in adopting cognitive computing across their PV landscape. Key considerations including how to initiate an automation odyssey, identifying targets for cognitive computing, the role of subject matter experts, and the impact of positive disruption will be explored.
Learning Objective : Define cognitive computing and how it differs from robotic process automation; Describe the in-depth process for training cognitive systems along with the required iterative training processes; Identify key stakeholders and business impacts.
Speaker(s)
Training Artificial Intelligent System for Pharmacovigilance: Practical Considerations and Guidance
Cartic Ramakrishnan, PHD
IBM Watson Health, United States
Senior Technical Staff Member, Lead Cognitive Scientist, Life Sciences
The Future of Pharmacovigilance After Full Industry Disruption from Cognitive Automation
Glenn Carroll, MBA
Deloitte, United States
Principal
Our Journey Toward Touchless Case Management
Caroline Rosewell, MBA
Eli Lilly and Company, United States
VP, Global Medicines Quality